Artivion, Inc. (AORT)
The price, the headline numbers and the latest news, in one place.
Artivion, Inc. (AORT) Stock Price, Analysis & Data
| Bid | 25.53 |
| Market Cap | 1.25B |
| Revenue (ttm) | 471M |
| Net Income (ttm) | -3.19M |
| 1.25 | |
| -0.06 | |
| n/a | |
| 32.71 | |
| P/B (ttm) | 2.79 |
| P/S (ttm) | 2.64 |
| Earnings Date | Feb 17, 2022 |
| Ask | 26.5 |
| Volume | 418,342 |
| Avg. Volume (20D) | 736,144 |
| Open | 25.37 |
| Previous Close | 25.62 |
| Day's Range | 25.25 - 25.69 |
| 52-Week Range | 19.16 - 48.25 |
| Analyst | n/a |
| Price Target | 42 (64.25%) |
| Dividends | n/a |
| Ex-Dividend Date | Dec 9, 2015 |
About AORT
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent g...
Financial Performance
In 2025, Artivion's revenue was 441.33M, an increase of 13.59% compared to the previous year's 388.54M. Earnings were 9.77M, a decrease of -173.12%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for AORT stock is "null". The 12-month stock price forecast is 42, which is upside of 64.25% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $125.76M misses estimates by $0, with 11.32% YoY growth.
- EPS of 0.13 exceeds estimates by 0.03, with -45.83% YoY decline.
Analysts project revenue of ... Upgrade


